JP2020503273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503273A5 JP2020503273A5 JP2019529206A JP2019529206A JP2020503273A5 JP 2020503273 A5 JP2020503273 A5 JP 2020503273A5 JP 2019529206 A JP2019529206 A JP 2019529206A JP 2019529206 A JP2019529206 A JP 2019529206A JP 2020503273 A5 JP2020503273 A5 JP 2020503273A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- antibody
- human
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 78
- 102000049823 human TIGIT Human genes 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 76
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 230000004614 tumor growth Effects 0.000 claims description 17
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 14
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 14
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 12
- 206010038038 rectal cancer Diseases 0.000 claims description 12
- 201000001275 rectum cancer Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000000112 colonic effect Effects 0.000 claims description 10
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 9
- 108010048507 poliovirus receptor Proteins 0.000 claims description 9
- 108091092878 Microsatellite Proteins 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 6
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229960005386 ipilimumab Drugs 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 4
- 102000048776 human CD274 Human genes 0.000 claims 4
- 102000048362 human PDCD1 Human genes 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 229960003852 atezolizumab Drugs 0.000 claims 3
- 229950002916 avelumab Drugs 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 3
- 230000002357 endometrial effect Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 229950010968 romosozumab Drugs 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 230000005751 tumor progression Effects 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022103151A JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427903P | 2016-11-30 | 2016-11-30 | |
| US62/427,903 | 2016-11-30 | ||
| US201762479609P | 2017-03-31 | 2017-03-31 | |
| US62/479,609 | 2017-03-31 | ||
| PCT/US2017/063918 WO2018102536A1 (en) | 2016-11-30 | 2017-11-30 | Methods for treatment of cancer comprising tigit-binding agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022103151A Division JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503273A JP2020503273A (ja) | 2020-01-30 |
| JP2020503273A5 true JP2020503273A5 (enExample) | 2021-10-14 |
| JP7126269B2 JP7126269B2 (ja) | 2022-08-26 |
Family
ID=62241934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529206A Active JP7126269B2 (ja) | 2016-11-30 | 2017-11-30 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
| JP2022103151A Pending JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022103151A Pending JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11230596B2 (enExample) |
| EP (1) | EP3548071A4 (enExample) |
| JP (2) | JP7126269B2 (enExample) |
| KR (1) | KR102461228B1 (enExample) |
| CN (1) | CN110662552A (enExample) |
| AU (1) | AU2017368155B2 (enExample) |
| BR (1) | BR112019010943A8 (enExample) |
| CA (1) | CA3044664C (enExample) |
| IL (1) | IL266847B2 (enExample) |
| MX (1) | MX2019006072A (enExample) |
| NZ (1) | NZ753515A (enExample) |
| RU (1) | RU2765410C2 (enExample) |
| WO (1) | WO2018102536A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE036780T2 (hu) | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CA3044664C (en) | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| US11021537B2 (en) | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| CN108948182A (zh) * | 2018-07-25 | 2018-12-07 | 中国人民解放军第四军医大学 | Tigit-ecd重组蛋白抗同种异体免疫排斥反应的应用 |
| TWI728400B (zh) * | 2018-07-26 | 2021-05-21 | 美商美國禮來大藥廠 | Cd226促效劑抗體 |
| EP3898677A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| AU2020290916A1 (en) * | 2019-06-13 | 2021-11-04 | Green Cross Corporation | Antibody to TIGIT and use thereof |
| JP7122354B2 (ja) * | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗ｔｉｇｉｔ抗体および使用方法 |
| US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| EP4147053B1 (en) | 2020-05-07 | 2026-01-28 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| EP4232068A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| EP4232069A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| JP2024500065A (ja) * | 2020-12-03 | 2024-01-04 | シャタック ラボ，インコーポレイテッド | Ｔｉｇｉｔベースのキメラタンパク質及びｌｉｇｈｔベースのキメラタンパク質を使用してがんを処置する方法 |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| CA3213917A1 (en) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
| WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| JP2024527049A (ja) | 2021-07-28 | 2024-07-19 | ジェネンテック， インコーポレイテッド | がんを治療するための方法及び組成物 |
| WO2023017191A1 (en) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| US20250179176A1 (en) | 2022-05-02 | 2025-06-05 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| KR20230168273A (ko) * | 2022-06-03 | 2023-12-13 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025188136A1 (en) * | 2024-03-04 | 2025-09-12 | Abl Bio, Inc. | Anti-tigit/anti-4-1bb bispecific antibodies and uses thereof |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7282570B2 (en) | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20080050809A1 (en) | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| WO2003068943A2 (en) | 2002-02-13 | 2003-08-21 | Incyte Corporation | Secreted proteins |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| DE60335552D1 (de) | 2002-09-11 | 2011-02-10 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US7550800B2 (en) | 2003-06-06 | 2009-06-23 | Chih-Hsin Wang | Method and apparatus transporting charges in semiconductor device and semiconductor memory device |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| ES2609429T3 (es) | 2005-05-12 | 2017-04-20 | Zymogenetics, Inc. | Composiciones y métodos para modular respuestas inmunitarias |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1932857A1 (en) | 2005-10-07 | 2008-06-18 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
| US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| CA2664738C (en) | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| PE20081456A1 (es) | 2006-10-06 | 2008-11-27 | Takeda Pharmaceutical | Anticuerpo monoclonal contra nectina 2 |
| DE102008028564A1 (de) | 2007-07-03 | 2009-01-08 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Hydrauliksystem zum Erzeugen eines Vorsteuerdruckes zum Ansteuern einer Getriebekomponente |
| MX354993B (es) | 2007-07-09 | 2018-03-28 | Genentech Inc | Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos. |
| HUE036780T2 (hu) | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| NZ601743A (en) | 2010-02-12 | 2014-11-28 | Oncomed Pharm Inc | Methods for identifying and isolating cells expressing a polypeptide |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| KR102003075B1 (ko) | 2011-02-23 | 2019-07-23 | 에프. 호프만-라 로슈 아게 | 인간 il33r에 대한 항체 및 이의 용도 |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| KR20150090919A (ko) * | 2012-12-04 | 2015-08-06 | 온코메드 파마슈티칼스, 인크. | 결합제를 사용한 면역요법 |
| CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| US9062104B2 (en) | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| AU2014290069B2 (en) * | 2013-07-16 | 2019-01-03 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US20170107300A1 (en) | 2014-03-21 | 2017-04-20 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| JP2017522311A (ja) * | 2014-07-16 | 2017-08-10 | ジェネンテック， インコーポレイテッド | Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法 |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| MY198017A (en) | 2014-08-19 | 2023-07-26 | Merck Sharp & Dohme | Anti-tigit antibodies |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| KR20170072343A (ko) * | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| EP3240908A2 (en) | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Methods and compositions for prognosis and treatment of cancers |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| WO2017030823A2 (en) | 2015-08-14 | 2017-02-23 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| WO2017037707A1 (en) | 2015-09-02 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| AU2016322934A1 (en) | 2015-09-14 | 2018-04-12 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta |
| KR20250021613A (ko) | 2015-09-25 | 2025-02-13 | 제넨테크, 인크. | 항-tigit 항체 및 이의 이용 방법 |
| KR20180068990A (ko) | 2015-10-01 | 2018-06-22 | 포텐자 테라퓨틱스, 인코포레이티드 | 항-tigit 항체-결합 단백질 및 이의 사용 방법 |
| US10537633B2 (en) | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| CA3044664C (en) * | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| MX2019010206A (es) | 2017-02-28 | 2019-12-11 | Seattle Genetics Inc | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). |
| WO2018187191A1 (en) * | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| US11021537B2 (en) | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
| WO2018220446A1 (en) * | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| KR20200041834A (ko) * | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
| US20210069241A1 (en) * | 2017-10-20 | 2021-03-11 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| EP3781596A1 (en) * | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| AT521173B1 (de) | 2018-06-27 | 2019-11-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegewerkzeug mit Distanzelement |
-
2017
- 2017-11-30 CA CA3044664A patent/CA3044664C/en active Active
- 2017-11-30 AU AU2017368155A patent/AU2017368155B2/en active Active
- 2017-11-30 WO PCT/US2017/063918 patent/WO2018102536A1/en not_active Ceased
- 2017-11-30 RU RU2019115428A patent/RU2765410C2/ru active
- 2017-11-30 US US16/464,820 patent/US11230596B2/en active Active
- 2017-11-30 JP JP2019529206A patent/JP7126269B2/ja active Active
- 2017-11-30 CN CN201780074119.5A patent/CN110662552A/zh active Pending
- 2017-11-30 BR BR112019010943A patent/BR112019010943A8/pt unknown
- 2017-11-30 NZ NZ753515A patent/NZ753515A/en not_active IP Right Cessation
- 2017-11-30 KR KR1020197017345A patent/KR102461228B1/ko active Active
- 2017-11-30 MX MX2019006072A patent/MX2019006072A/es unknown
- 2017-11-30 EP EP17876358.7A patent/EP3548071A4/en not_active Withdrawn
-
2019
- 2019-05-23 IL IL266847A patent/IL266847B2/en unknown
-
2020
- 2020-12-11 US US17/119,883 patent/US11136384B2/en active Active
-
2021
- 2021-12-09 US US17/547,178 patent/US20220340653A1/en not_active Abandoned
-
2022
- 2022-06-28 JP JP2022103151A patent/JP2022130561A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503273A5 (enExample) | ||
| RU2019115428A (ru) | Способы лечения рака, включающие связывающие tigit агенты | |
| US20230115328A1 (en) | Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer | |
| AU2020276242B2 (en) | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer | |
| JP6877147B2 (ja) | 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法 | |
| JP2023126946A (ja) | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP6805428B2 (ja) | Ｃｅａｃａｍ１に対するヒト化抗体 | |
| JP2018503365A5 (enExample) | ||
| JPWO2020232019A5 (enExample) | ||
| JP2023011902A (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| JPWO2019143607A5 (enExample) | ||
| JP2024519449A (ja) | がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 | |
| KR20230056761A (ko) | Pd-1 저해제의 투여에 의한 암 치료 방법 | |
| WO2025058453A1 (en) | Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies | |
| Brogna et al. | Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges: MR Brogna et al. | |
| EP4694894A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor | |
| KR20230159833A (ko) | Pd-1 저해제의 투여에 의한 폐암 치료 방법 | |
| JPWO2022270523A5 (enExample) | ||
| EA049485B1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| JPWO2023057534A5 (enExample) |